title: Leukemia following radiotherapy for uterine bleeding.
abstract: Mortality due to leukemia among 4483 women treated with radiation to control uterine bleeding between 1925 and 1965 was twice as high as expected based on U.S. population rates (standardized mortality ratio (SMR) = 2.0; 95% confidence interval (CI): 1.4 to 2.8). Women were followed for an average of 26.4 years. Relative risk was highest 2 to 5 years after treatment (SMR = 8.1) and among women over 55 years at irradiation (SMR = 5.8). The usual method of treatment was intrauterine radium. Average radiation dose to active bone marrow was estimated on the basis of original radiotherapy records (median, 53 cGy). A linear dose-response model provided an adequate fit to the data. The average excess relative risk was 1.9% per cGy (95% CI: 0.8 to 3.2), and the average absolute risk was 2.6 excess leukemia deaths per million women per year per cGy (95% CI: 0.9 to 4.8). Chronic myeloid leukemia predominated during the first 15 years following exposure, whereas acute leukemias and chronic lymphatic leukemia were most common thereafter. The radiation doses experienced during treatment of benign gynecologic disease appear to result in greater leukemia risk per cGy average marrow dose than the considerably higher doses used to treat malignant disease, perhaps because of a decreased likelihood of killing potentially leukemic cells.
authors.affiliation: Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115.
authors.forename: P D
authors.initials: PD
authors.lastname: Inskip
authors.forename: R R
authors.initials: RR
authors.lastname: Monson
authors.forename: J K
authors.initials: JK
authors.lastname: Wagoner
authors.forename: M
authors.initials: M
authors.lastname: Stovall
authors.forename: F G
authors.initials: FG
authors.lastname: Davis
authors.forename: R A
authors.initials: RA
authors.lastname: Kleinerman
authors.forename: J D
authors.initials: JD
authors.lastname: Boice
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000453:epidemiology / Q000209:etiology / Q000401:mortality; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000453:epidemiology / Q000209:etiology / Q000401:mortality; D007953:Leukemia, Radiation-Induced / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality; D008404:Massachusetts / Q000453:epidemiology; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects*; D011883:Radium / Q000627:therapeutic use; D012237:Rhode Island / Q000453:epidemiology; D014592:Uterine Hemorrhage / Q000532:radiotherapy*
chemical_list: D011883:Radium